Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
Kristen Hege(University of California, San Francisco), Stephen A. Sherwin(University of California, San Francisco), Robert S. Warren(University of California, San Francisco), Emily K. Bergsland(University of California, San Francisco), George A. Fisher(Stanford University), Carl H. June(University of Pennsylvania), John Nemunaitis(Gradalis (United States)), Jeffrey Schlom(National Cancer Institute), Andy Lin(Genesys (United States)), James G. McArthur(Genesys (United States))
Cited by 320
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k